EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis

Robert J Fox iD, Amit Bar-Or, Anthony Traboulsee, Celia Oreja-Guevara, Gavin Giovannoni, Patrick Vermersch, Sana Syed, Ye Li, Wendy S Vargas, Timothy J Turner, Erik Wallstroem, Daniel S Reich iD und 1 weitere

New England Journal of Medicine · 15.05.2025 · 392 (19) · 1883-1892

DOI: 10.1056/nejmoa2415988 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 15.05.2025. Verfasst von Robert J Fox und 12 weiteren Autor:innen. Beteiligte Einrichtung: Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Multiple Sclerosis, Chronic Progressive, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 158-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseMultiple Sclerosis, Chronic ProgressiveProtein Kinase InhibitorsTyrosine Kinase InhibitorsAdultFemaleHumansMaleMiddle AgedDisability EvaluationDisease ProgressionDouble-Blind MethodKaplan-Meier EstimateAlanine TransaminaseLiverTreatment Outcome

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsTyrosine Kinase InhibitorsAlanine Transaminase

Autor:innen und Institutionen

  • Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland.
  • Center for Neuroinflammation and Experimental Therapeutics, Department of Neurology, University of Pennsylvania, Philadelphia.
  • Division of Neurology, University of British Columbia, Vancouver, Canada.
  • Department of Neurology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid.
  • Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid.
  • Queen Mary University of London, Blizard Institute, Faculty of Medicine and Dentistry, London.

ORCID-Profile: Robert J Fox, Daniel S Reich

Förderung

  • Sanofi

Zitieren

APA

Fox, R. J., Bar-Or, A., Traboulsee, A., Oreja-Guevara, C., Giovannoni, G., Vermersch, P., Syed, S., Li, Y., Vargas, W. S., Turner, T. J., Wallstroem, E., Reich, D. S., & HERCULES Trial Group (2025). Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. New England Journal of Medicine, 392(19), 1883-1892. https://doi.org/10.1056/nejmoa2415988

Vancouver

Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, et al. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. New England Journal of Medicine. 2025;392(19):1883-1892. doi:10.1056/nejmoa2415988

BibTeX
@article{Fox2025,
  author = {Fox, Robert J and Bar-Or, Amit and Traboulsee, Anthony and Oreja-Guevara, Celia and Giovannoni, Gavin and Vermersch, Patrick and Syed, Sana and Li, Ye and Vargas, Wendy S and Turner, Timothy J and Wallstroem, Erik and Reich, Daniel S and HERCULES Trial Group, HERCULES Trial Group},
  title = {Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {19},
  pages = {1883--1892},
  doi = {10.1056/nejmoa2415988}
}
Kostenlos starten →